Currently, Mineralys Therapeutics Inc [MLYS] is trading at $16.10, up 5.09%. An important factor to consider is whether the stock is rising or falling in short-term value. The MLYS shares have gain 5.99% over the last week, with a monthly amount glided 21.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on July 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on April 02, 2024, and set its price target to $30. On March 07, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 07, 2023. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on March 07, 2023. In a note dated March 07, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $40 on this stock.
This stock has fluctuated between a low of $8.24 and a high of $18.38 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $16.10 at the most recent close of the market. An investor can expect a potential return of 179.5% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.71 and Total Capital is -0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mineralys Therapeutics Inc [NASDAQ:MLYS] is 26.48. On the other hand, the Quick Ratio is 26.48, and the Cash Ratio is 12.33.
Transactions by insiders
Recent insider trading involved Rodman David Malcom, Chief Medical Officer, that happened on May 14 ’25 when 11366.0 shares were sold. Officer, Rodman David Malcom completed a deal on May 14 ’25 to buy 11366.0 shares. Meanwhile, Director Slingsby Brian Taylor bought 0.26 million shares on Mar 13 ’25.
